Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Indoor Rowing in Adults With Impaired Glucose Regulation: a Pilot Study
Verified date | May 2015 |
Source | University of Leicester |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: National Research Ethics Service |
Study type | Interventional |
Primary research question: What is the effect of indoor rowing, under the ideal
circumstances of a laboratory setting, on glucose control in adults with impaired glucose
control?
Secondary research question: Is it possible to develop a full-scale study of the benefits of
indoor rowing under the usual circumstances of a community setting?
Why? It is good practice to conduct a small pilot study before embarking on an expensive
full-scale study.
What? Around 150 minutes of aerobic exercise and around 150 minutes of resistance exercise
per week are necessary to meet prevailing recommendations for adults with impaired glucose
control. Around 120 minutes of indoor rowing per week might be a less time-consuming
alternative to prevailing recommendations because indoor rowing involves a combination of
aerobic and resistance exercise.
Who? Twenty men and postmenopausal women aged 45-65 years with impaired glucose regulation,
such as those with type 2 diabetes. Eligible volunteers will not have smoked in the last
year, will not have exercised regularly in the last six months, and will not be taking any
form of diabetes medication other than metformin. Eligible volunteers will have stable
weight and a body mass index of 25-40.
Where and how? Before and after the exercise intervention, glucose control (postprandial
blood glucose concentrations) will be assessed at Leicester Diabetes Centre and cardiac
function (MRI) will be assessed at Glenfield Hospital. During the exercise intervention,
participants will use an indoor rower three times per week for 12 weeks at Leicester
Diabetes Centre. Participants will be taught how to row correctly and the duration and
intensity will gradually increase. In order to inform the design of a full-scale trial,
recruitment rate will be assessed, adherence will be monitored, and a third party will
interview participants to find out if the intervention and assessments are feasible and
acceptable.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the study. - Participant is willing to allow their general practitioner to be informed of any incidental findings. - Eligible men will be 45 to 65 years of age. - Eligible women will be 45 to 65 years of age and will be postmenopausal, defined as no menstrual period in the last 12 months. - Body mass index of 25 to 40 kg·m-2. - Stable weight, defined as self-reported weight change of less than 5 kg in the last six months. - Impaired glucose regulation, defined as impaired fasting glucose (fasting plasma glucose of 5.6 to 6.9 mmol·l-1), or impaired glucose tolerance (two-hour plasma glucose in the 75-g oral glucose tolerance test of 7.8 to 11.0 mmol·l-1), or haemoglobin A1C of 6.0% or greater, or type 2 diabetes (fasting plasma glucose of 7.0 mmol·l-1 or greater on two occasions). - Volunteers with type 2 diabetes will either be treatment naïve or will have been taking a stable dose of metformin for at least four weeks prior to study entry. - White European ethnicity. There are ethnic differences in cardiovascular disease risk and prevailing definitions of dyslipidaemia, insulin resistance and diabetes cannot account for these differences (Forouhi et al., Diabetologia, 2006, 49, 2580-8; Tillin et al., Journal of the American College of Cardiology, 2013, 61, 1777-86). Therefore, in order to make valid inferences, the investigators will only include white Europeans on this occasion. - Little or no participation in exercise: eligible volunteers will not have been exercising two or more times per week for 20 minutes or longer for the last six months. Exclusion Criteria: - Volunteers with type 2 diabetes will be excluded if they are taking any form of diabetes medication other than metformin. - Known cardiovascular disease. - Symptoms of angina. - Resting systole blood pressure =180 mm Hg or diastolic blood pressure =110 mm Hg. - Statin use. - Beta-blocker use. - Verapamil use. - Hormone replacement therapy. - Any smoking in the last year. - Any absolute contraindication to exercise testing. - Abnormal exercise test. - Inability to undertake an exercise programme for any reason. - Participation in a research study involving an investigational produce in the past 12 weeks. - Female volunteers who are pregnant, lactating or planning pregnancy during the course of the study. Pregnancy will be discussed during the consent procedure and the investigators will provide those in any doubt with a pregnancy test kit. - Chronic kidney disease (EGFR of =30). - Any metal implants. |
Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United Kingdom | Leicester Diabetes Centre | Leicester |
Lead Sponsor | Collaborator |
---|---|
University of Leicester | Medtronic, Wellcome Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Glucose control | Glucose control is indicated by postprandial glucose concentration, which will be assessed using a standardized meal test. | Changes from baseline (week 0) to post intervention (week 0 versus week 13 and week 0 versus week 14) | No |
Primary | Change in Cardiac function | Cardiac function is indicated by diastolic strain rate, which will be assessed using magnetic resonance imaging. | Changes from baseline (week 0) to post intervention (week 13) | No |
Secondary | Recruitment rate | Participants will be recruited via general practice databases and the investigators will calculate the proportion of eligible-and-invited individuals who agree to take part in the study. | Response rate to up to seven months of recruitment | No |
Secondary | Feasibility and acceptability as assessed by Semi-structured interviews | The interview during the intervention will focus on recruitment literature, screening procedures, baseline assessments, and first impressions of indoor rowing. The interview after the intervention will focus on participants' experiences of indoor rowing, including their likes, dislikes and suggestions. Each interview will last around 30 to 60 minutes and will be led by an independent researcher not involved in the day-to-day conduct of the study. Some questions and topics will be predetermined, but conversations will be allowed to flow freely and change according to the interviewer's discretion. | Semi-structured interviews will be conducted during (week 5 or 6) and after (week 14) the intervention | No |
Secondary | Change in Sample size in a full-scale trial | Haemoglobin A1C is a longer-term marker of glucose control and may be an appropriate outcome for a full-scale trial. The investigators wish to use the sample standard deviation from this pilot study in haemoglobin A1C (and, possibly, other variables) to estimate the population standard deviation and, thus, the power of a full-scale trial. | Changes from baseline (week 0) to post intervention (week 13) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |